AU2022288895A1 - Formulation containing dihydropyridazine-3,5-dione derivative - Google Patents

Formulation containing dihydropyridazine-3,5-dione derivative Download PDF

Info

Publication number
AU2022288895A1
AU2022288895A1 AU2022288895A AU2022288895A AU2022288895A1 AU 2022288895 A1 AU2022288895 A1 AU 2022288895A1 AU 2022288895 A AU2022288895 A AU 2022288895A AU 2022288895 A AU2022288895 A AU 2022288895A AU 2022288895 A1 AU2022288895 A1 AU 2022288895A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
less
formula
compound represented
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022288895A
Other languages
English (en)
Inventor
Tomoyuki MINODA
Shigemori NATSUMOTO
Kenichi Sakai
Ryusuke TAKANO
Hiromasa Uchiyama
Mayumi Yoshikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2022288895A1 publication Critical patent/AU2022288895A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2022288895A 2021-06-08 2022-06-08 Formulation containing dihydropyridazine-3,5-dione derivative Pending AU2022288895A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-096206 2021-06-08
JP2021096206 2021-06-08
PCT/JP2022/023076 WO2022260064A1 (ja) 2021-06-08 2022-06-08 ジヒドロピリダジン-3,5-ジオン誘導体を含有する製剤

Publications (1)

Publication Number Publication Date
AU2022288895A1 true AU2022288895A1 (en) 2024-01-18

Family

ID=84426023

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022288895A Pending AU2022288895A1 (en) 2021-06-08 2022-06-08 Formulation containing dihydropyridazine-3,5-dione derivative

Country Status (12)

Country Link
US (1) US20240293402A1 (cg-RX-API-DMAC7.html)
EP (1) EP4353233A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022260064A1 (cg-RX-API-DMAC7.html)
KR (1) KR20240018523A (cg-RX-API-DMAC7.html)
CN (1) CN117460511A (cg-RX-API-DMAC7.html)
AU (1) AU2022288895A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023023708A2 (cg-RX-API-DMAC7.html)
CA (1) CA3221186A1 (cg-RX-API-DMAC7.html)
IL (1) IL309056A (cg-RX-API-DMAC7.html)
MX (1) MX2023014507A (cg-RX-API-DMAC7.html)
TW (1) TW202317118A (cg-RX-API-DMAC7.html)
WO (1) WO2022260064A1 (cg-RX-API-DMAC7.html)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012012421A (es) 2010-04-28 2012-12-17 Astellas Pharma Inc Compuestos tetrahidrobenzotiofena.
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
PL2772490T3 (pl) 2011-10-27 2016-11-30 Aminoalkilo-podstawiona pochodna n-tienylobenzamidu
WO2014003153A1 (ja) 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
AU2014230552B2 (en) * 2013-03-13 2017-11-16 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative
US9499553B2 (en) * 2013-03-13 2016-11-22 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same
SMT202100481T1 (it) 2014-08-18 2021-09-14 Alkermes Pharma Ireland Ltd Composizioni per profarmaci di aripiprazolo
EP4374877A3 (en) 2014-09-12 2024-07-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical containing sodium-dependent phosphate transporter inhibitor and phosphorus adsorbent for use in the prevention, treatment or suppression of chronic kidney disease, arteriosclerosis associated with vascular calcification, or ectopic calcification.
MX376202B (es) 2016-08-15 2025-03-07 Lilly Co Eli Compuestos de tiofeno condensado utiles como inhibidores de napi-iib.
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
US12097204B2 (en) * 2018-09-03 2024-09-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof

Also Published As

Publication number Publication date
KR20240018523A (ko) 2024-02-13
CN117460511A (zh) 2024-01-26
MX2023014507A (es) 2024-01-26
EP4353233A1 (en) 2024-04-17
BR112023023708A2 (pt) 2024-01-30
US20240293402A1 (en) 2024-09-05
IL309056A (en) 2024-02-01
TW202317118A (zh) 2023-05-01
WO2022260064A1 (ja) 2022-12-15
JPWO2022260064A1 (cg-RX-API-DMAC7.html) 2022-12-15
EP4353233A4 (en) 2025-06-25
CA3221186A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
CA2682598C (en) Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
US20140248347A1 (en) Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
US10653626B2 (en) Powder for oral suspension containing lamotrigine
KR101352130B1 (ko) 디클로페낙 제제 및 이용 방법
RS20050470A (sr) LEKOVI U ČVRSTOM STANjU ZA ORALNU UPOTREBU
US20230277529A1 (en) Stable pharmaceutical composition for oral administration
JP6367042B2 (ja) ボリコナゾールを含む医薬組成物
US20240293402A1 (en) FORMULATION CONTAINING DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE (as amended)
US20250325517A1 (en) Oral dosage forms of elraglusib
HK40104119A (en) Formulation containing dihydropyridazine-3,5-dione derivative
EP3162368A1 (en) Pharmaceutical composition for oral administration
HK40119846A (en) Oral dosage forms of elraglusib
KR20160079178A (ko) 실로도신을 포함하는 고형 경구제제
CN107137374A (zh) 帕洛诺司琼的固体药物组合物

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ FORMULATION CONTAINING DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE